In the first two quarters of 20 12, the main income of the pharmaceutical industry was 809.4 billion yuan, a year-on-year increase of19.1%; The total profit was 86,543.8+007 billion yuan, up 65,438+07.7% year-on-year, and the sales profit rate was 65,438+00%. Macro data show that in terms of production, the added value of the pharmaceutical industry exceeds the average growth rate of the whole industry: in the first quarter, the added value of the pharmaceutical industry increased by 16.6%, exceeding the whole industry by 5 percentage points, and in the second quarter it increased by 14.3%, exceeding the whole industry by 4 percentage points; In terms of benefits, the profits of various industries increased by -2.2% year-on-year, and the pharmaceutical industry increased by nearly 20%. In the first quarter of this year, the sales profit rate of the pharmaceutical industry was 9.6%, and in the second quarter, it was 10%, which was 4.3 percentage points and 4.6 percentage points higher than the national industrial average respectively. From June to July of 2065,438+02, the overall sales revenue of pharmaceutical manufacturing industry increased by 65,438+09.08%, and the total profit increased by 65,438+07.76. In terms of profit, although the growth rate of the industry has slowed down compared with the same period of 20 1 1, the monthly growth rate of total profit has been increasing continuously since 20 12, and the trend is good.
At present, the core idea of the 12th Five-Year Plan of China pharmaceutical industry is also "industrial transformation and technological upgrading", which is essentially different from the 11th Five-Year Plan. Product standards should be upgraded, safer and more effective, and the quality assurance system should be improved, which will greatly improve the production level of China's pharmaceutical industry. In China pharmaceutical industry cluster, a number of enterprises such as Hengrui, Xiansheng, Lvye, Tasly, Kangyuan, Dongfang Sunshine, Fosun, Shi Yao, Qilu and Chen Xin insist on independent innovation and have made remarkable achievements in market competition. National basic innovation has also greatly promoted industrial innovation and upgrading. In recent years, China has launched a major scientific and technological project to create new drugs, which has brought infinite impetus to the industry. Through planning guidance and policy support, the technological innovation system combining "Industry-University-Research" in the pharmaceutical industry has been continuously improved, the innovation ability has been continuously enhanced, and the development of new products and technologies has achieved remarkable results. Among them, innovative drugs such as antofloxacin hydrochloride and recombinant Helicobacter pylori vaccine were approved for marketing; Large-scale cell culture and other technologies have been applied to the production of genetically engineered drugs; Industrialization of monoclonal antibodies such as recombinant human tumor necrosis factor receptor antibody fusion protein; Biosynthesis partially replaces chemical method and has been successfully applied to the production of amoxicillin, cefalexin and other products. A number of new generic drugs such as pioglitazone and clopidogrel quickly formed a market scale; Advanced technologies such as superfine grinding and supercritical extraction are popularized and applied in the production of traditional Chinese medicine; The production technology level of a number of API varieties has been significantly improved, and the production cost has been declining.
During the "Twelfth Five-Year Plan" period, China will form 1-3 national large-scale pharmaceutical business groups with annual sales exceeding 100 billion, and 20 regional pharmaceutical circulation enterprises with annual sales exceeding 10 billion; The annual sales of the top 100 pharmaceutical wholesale enterprises account for more than 85% of the total pharmaceutical wholesale, and the annual sales of the top 100 pharmaceutical retail chain enterprises account for more than 60% of the total pharmaceutical retail; The proportion of chain pharmacies in all retail stores has increased to more than 2/3. The grassroots circulation network below the county level is more sound. The comprehensive strength of backbone enterprises is close to the advanced level of international circulation enterprises, with an average annual growth of 20% in total industrial output value and 16% in industrial added value, reaching 20 15. There are more than five enterprises with sales revenue exceeding 50 billion yuan, and more than 6543.8+000 enterprises with sales revenue exceeding 6543.8+000 billion yuan, of which sales revenue accounts for 6543.8+000.
This research report was written by Puhua Consulting Company of China Research Institute. Based on a large number of detailed market research, it mainly relies on a large number of materials published and provided by the National Bureau of Statistics, the National Development and Reform Commission, the State Administration for Industry and Commerce, the Health Bureau, the National Business Information Center, the China Economic Prosperity Monitoring Center, the China Pharmaceutical Industry Association, China Industry Research Network and various related newspapers and magazines at home and abroad. Firstly, the definition and classification of medicine are introduced, then the development status of medicine industry is analyzed, and then the medicine industry is deeply studied. Then it expounds the competitive pattern of the pharmaceutical industry, analyzes the operating conditions of key enterprises, and finally analyzes the development prospects and trends of the pharmaceutical industry. At the same time, China Research Institute Puhua conducted a comprehensive investment analysis on the pharmaceutical industry. This report is a valuable investment decision-making reference report for pharmaceutical production, management, scientific research enterprises and related research units.